BPC-157 for Tendon and Gut Healing, and What the Research Shows So Far

Patients ask me about BPC-157 almost every week, usually after a training partner, a physical therapist, or a podcast told them it would heal a tendon that has bothered them for months. The injury is typically a sore Achilles, a partial rotator cuff tear, or an elbow that flares with every set of pull-ups, and the question is a fair one, can an injection speed this up? The research behind BPC-157 is striking and lopsided, with dozens of rat studies reporting faster healing and almost no controlled data in people.

Where BPC-157 came from

BPC-157, short for body protection compound 157, is a chain of 15 amino acids that copies a partial sequence of a protein first isolated from human gastric juice [1]. Predrag Sikiric's pharmacology group at the University of Zagreb has studied it since the early 1990s, first as an anti-ulcer agent, since a peptide that stays intact in stomach acid is a natural candidate for protecting the gut lining. In their rat models it healed lesions along the whole digestive tract, including esophagitis, surgical reconnections of the bowel, and fistulas, the abnormal channels that form between the bowel and the skin [2].

The same group writes that a version of the peptide called PL 14736 went into clinical trials for inflammatory bowel disease [2], yet a PubMed search turns up no published results from those trials. This means that when someone tells you BPC-157 is proven for gut healing, the proof they're describing is in rats. If the gut is your main concern, the measures in our post on gut health and minerals carry far more human evidence than any peptide does.

What it does in injured rats

The animal results in tendon are consistent and large. In a 2003 study in the Journal of Orthopaedic Research, Staresinic and colleagues cut the Achilles tendon of rats, left a gap between the ends, and gave a daily injection of BPC-157 or saline into the abdominal cavity. The treated tendons carried more load before failing, the rats scored higher on a functional walking index, and under the microscope the repair tissue held more fibroblasts (the cells that build connective tissue) and more collagen, while the control tendons healed poorly [3].

Other injury models point the same way. Vasireddi and colleagues, in a 2025 systematic review in the HSS Journal, screened 544 articles and included 36, of which 35 were preclinical and one was clinical, and the included studies reported improved structural and biomechanical outcomes across muscle, tendon, ligament, and bone injury models [4].

How it might work

Three mechanisms have laboratory support, and the most useful work comes from a second, independent group at Chang Gung University in Taiwan.

The first mechanism is angiogenesis, the formation of new blood vessels. Tendons have a sparse blood supply, which is one reason they heal slowly (I covered how tendon cells maintain their collagen in our post on fluoroquinolone tendon damage). Hsieh and colleagues, in a 2017 study in the Journal of Molecular Medicine, found that BPC-157 increased vessel density in a chick embryo assay, sped the return of blood flow to the oxygen-starved hind limb of rats, and raised the expression of VEGFR2, the receptor through which vascular endothelial growth factor tells a vessel to grow. Downstream of that receptor it activated endothelial nitric oxide synthase, the enzyme that makes nitric oxide in the vessel wall [5].

The second mechanism is fibroblast movement. Fibroblasts grew out of rat tendon explants faster in the presence of BPC-157, survived oxidative stress better, and migrated more, though the peptide didn't make them divide any faster. The signal ran through FAK and paxillin, two proteins a cell uses to grip its surroundings and crawl [1].

The third mechanism is growth hormone signaling. In cultured rat tendon fibroblasts, BPC-157 raised the expression of the growth hormone receptor, so the cells multiplied more when the researchers added growth hormone [6].

Each of these is a finding in cultured cells, chick embryos, or rats. They make the healing story plausible, which isn't the same as showing that it happens in a human shoulder.

What we have in humans

No randomized controlled trial has tested BPC-157 for any musculoskeletal injury in humans. The human orthopedic evidence consists of one retrospective chart review. Lee and Padgett, in a 2021 report in Alternative Therapies in Health and Medicine, phoned 16 patients from a single Florida clinic, most of them six months to a year after an injection of BPC-157 into a painful knee (four had received thymosin beta-4 along with it), and 14 of the 16 said their pain had improved [7]. The study had no control group, no imaging, no standardized measure of pain or function, and a mix of diagnoses, so nobody can separate the peptide's effect from the natural course of knee pain, the placebo response, or the courtesy of a patient answering a call from their own doctor's office. I read it as a reason to run a trial, and not as evidence that the peptide works.

Safety data are thinner still. A 2025 pilot study infused up to 20 mg intravenously into two adults and found no change in markers of heart, liver, kidney, or thyroid function or in blood glucose [8], and two people can't tell us anything about uncommon harms. Pharmacokinetic work in rats and dogs found an elimination half-life under 30 minutes, with the body breaking the peptide into small fragments and then single amino acids [9], which leaves open how a molecule that disappears so quickly would drive weeks of repair. The systematic review found no clinical safety data at all [4].

Why I stay skeptical

Two features of this literature limit what any of us can claim. The first is that most of the animal work comes from a single laboratory. Gwyer and colleagues, reviewing the field in Cell and Tissue Research in 2019, observed that only a handful of research groups had studied the peptide in depth and that every published study reported a positive effect [10]. A literature with no failed dose, no unresponsive tissue, and no negative result should raise your guard, because real drugs don't behave that way, and independent replication is how medicine separates a true effect from an enthusiastic laboratory. The Taiwanese cell studies are a start, though a mechanism can't stand in for an outcome trial.

The second feature is the mechanism itself. A molecule that switches on VEGFR2 and grows new blood vessels does what a tumor needs to enlarge, and several cancer drugs work by blocking that same receptor pathway. No study has shown that BPC-157 causes or accelerates cancer, and none has followed humans long enough to find out. My read is that anyone with an active or recently treated cancer should stay away from it.

How we use it

Compounded BPC-157 isn't FDA-approved for any condition, and no approved drug is built on it. Professional sport bans it [4], so if you're subject to drug testing, don't use it. I'd also avoid it during pregnancy and breastfeeding, where nothing is known.

If you're considering it for a tendon or ligament, a few unglamorous steps come first, because they carry more human evidence than the peptide does.

• Get an accurate diagnosis, with imaging when the exam calls for it, since a complete tear needs a surgeon and no peptide will reattach it.
• Load the tendon, because progressive resistance training is the best-supported treatment for a chronically painful tendon and an injection doesn't replace it.
• Eat enough protein and protect your sleep, since your body lays down new collagen during recovery.
• Review your medications with your physician, because fluoroquinolone antibiotics and repeated corticosteroid injections both weaken tendon.
• Obtain it only through a physician and a licensed compounding pharmacy. The systematic review named unregulated manufacturing and contamination among the risks of these products [4].

When we prescribe BPC-157, we treat it as an experimental adjunct for a defined injury and a limited course, in someone without cancer who understands that the supporting evidence lives in rats, and we pair it with a loading program instead of offering it in place of one. I'd change that position quickly if a well-run randomized trial showed a benefit, and I'd change it as quickly in the other direction if one showed harm.

Ask a provider about BPC-157

References

1. Chang CH, Tsai WC, Lin MS, et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol (1985). 2011. PMID: 21030672
2. Sikiric P, Seiwerth S, Rucman R, et al. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Curr Pharm Des. 2011. PMID: 21548867
3. Staresinic M, Sebecic B, Patrlj L, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. J Orthop Res. 2003. PMID: 14554208
4. Vasireddi N, Hahamyan H, Salata MJ, et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS J. 2025. PMID: 40756949
5. Hsieh MJ, Liu HT, Wang CN, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl). 2017. PMID: 27847966
6. Chang CH, Tsai WC, Hsu YH, et al. Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules. 2014. PMID: 25415472
7. Lee E, Padgett B. Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. Altern Ther Health Med. 2021. PMID: 34324435
8. Lee E, Burgess K. Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study. Altern Ther Health Med. 2025. PMID: 40131143
9. He L, Feng D, Guo H, et al. Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs. Front Pharmacol. 2022. PMID: 36588717
10. Gwyer D, Wragg NM, Wilson SL. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell Tissue Res. 2019. PMID: 30915550